Thermal versus Mechanical hemostatic methods for high-risk non-variceal upper gastrointestinal bleeding in patients with antiplatelet/anticoagulant: A multicenter randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20251113005

Enrollment

Registered

2025-11-13

Start date

2025-11-24

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high-risk non-variceal upper gastrointestinal bleeding in patients with antiplatelet/anticoagulant NVUGIB, Thermal/Mechanical Endoscopic hemostasis, Antiplatelet/anticoagulant

Interventions

All patients will undergo therapeutic endoscopy within 24 hours after adequate resuscitation. Intravenous pantoprazole 80 mg will be administered according to standard clinical guidelines. Mechanical

Active Comparator Procedure/Surgery,Active Comparator Procedure/Surgery

Mechanical hemostasis ,Thermal hemostasis

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. High-risk NVUGIB patients with long-term indication for antiplatelet/anticoagulant who required endoscopic hemostasis 2. Age > 18 years old

Exclusion criteria

Exclusion criteria: 1. Culprit vessels size > 3 millimeters 2. Had prior endoscopic hemostasis intervention before this index bleeding episode within the last 4 weeks 3. Variceal bleeding, tumor bleeding 4. Required surgical therapy (perforated ulcer) 5. Pregnant women

Design outcomes

Primary

Measure	Time frame
Rebleeding within 30 days after initial endoscopy 30 days after intervention Case record form from clinical incidence	—

Secondary

Measure	Time frame
Initial hemostasis immediate after intervention Case record form from clinical incidence,Rebleeding within 7 days 7 days after intervention Case record form from clinical incidence,Blood transfusion required during hospitalization after first endoscopy in admission period Case record form from clinical incidence,Duration of ICU stay in admission period Case record form from clinical incidence,Duration of hospital stay in admission period Case record form from clinical incidence,Need for re-intervention theurapeutic endoscopy in admission period Case record form from clinical incidence,Need for angioembolization or surgical hemostasis in admission period Case record form from clinical incidence,Mortality rate at 30 days 30 days after intervention Case record form from clinical incidence	—

Measure

Time frame

Initial hemostasis immediate after intervention Case record form from clinical incidence,Rebleeding within 7 days 7 days after intervention Case record form from clinical incidence,Blood transfusion required during hospitalization after first endoscopy in admission period Case record form from clinical incidence,Duration of ICU stay in admission period Case record form from clinical incidence,Duration of hospital stay in admission period Case record form from clinical incidence,Need for re-intervention theurapeutic endoscopy in admission period Case record form from clinical incidence,Need for angioembolization or surgical hemostasis in admission period Case record form from clinical incidence,Mortality rate at 30 days 30 days after intervention Case record form from clinical incidence

—

Countries

Thailand

Contacts

Public ContactBorworn Siriprompatr

Phramongkutklao hospital

yoksk134@gmail.com0988515546

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026